首页> 美国卫生研究院文献>other >Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation
【2h】

Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation

机译:大肠菌素和美罗培南的复合颗粒制剂具有改善的体外细菌杀灭和雾化吸入特性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antibiotic combination therapy is promising for the treatment of lower respiratory tract infections caused by multi-drug resistant Gram-negative pathogens. Inhaled antibiotic therapy offers the advantage of direct delivery of the drugs to the site of infection, as compared to the parenteral administrations. In this study, we developed composite particle formulations of colistin and meropenem. The formulations were characterized for particle size, morphology, specific surface area, surface chemical composition, in-vitro aerosolization performance and in-vitro antibacterial activity. The combinations demonstrated enhanced antibacterial activity against clinical isolates of Acinetobacter baumannii N16870 and Pseudomonas aeruginosa 19147, when compared with antibiotic monotherapy. Spray-dried meropenem alone showed a poor aerosolization performance as indicated by a low fine particle fraction (FPF) of 32.5 ± 3.3%. Co-spraying with colistin improved the aerosolization of meropenem with up to a two-fold increase in the FPF. Such improvements in aerosolization can be attributed to the enrichment of colistin on the surface of composite particles as indicated by X-ray photoelectron spectroscopy (XPS) and time-of-flight secondary ion mass spectrometry (ToF-SIMS), and the increases in particle porosity. Intermolecular interactions between colistin and meropenem were observed for the combination formulations as measured by FT-IR. In conclusion, our results show that co-spray drying with colistin improves the antibacterial activity and aerosol performance of meropenem and produces a formulation with synergistic bacterial killing.
机译:抗生素联合疗法有望用于治疗由多重耐药革兰氏阴性病原体引起的下呼吸道感染。与肠胃外给药相比,吸入抗生素治疗具有将药物直接递送到感染部位的优势。在这项研究中,我们开发了大肠菌素和美洛培南的复合颗粒配方。对制剂的粒径,形态,比表面积,表面化学组成,体外雾化性能和体外抗菌活性进行了表征。与抗生素单一疗法相比,这些组合显示出对鲍曼不动杆菌N16870和铜绿假单胞菌19147的临床分离株具有增强的抗菌活性。单独的喷雾干燥美罗培南显示出较差的雾化性能,如32.5±3.3%的低细颗粒分数(FPF)所示。与粘菌素共同喷雾改善了美罗培南的雾化,FPF最多提高了两倍。气雾化的这种改善可归因于复合粒子表面上粘菌素的富集,如X射线光电子能谱(XPS)和飞行时间二次离子质谱(ToF-SIMS)所表明的,以及粒子数量的增加孔隙率。通过FT-IR测量,观察到大肠菌素和美罗培南之间的分子间相互作用。总之,我们的结果表明,与粘菌素共同喷雾干燥可改善美罗培南的抗菌活性和气雾剂性能,并产生具有协同杀菌作用的制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号